Literature DB >> 10696245

HA-HAase urine test. A sensitive and specific method for detecting bladder cancer and evaluating its grade.

V B Lokeshwar1, N L Block.   

Abstract

Hyaluronic acid and HAase are intricately associated with the biology of bladder tumor angiogenesis and metastasis. Tumor-associated HA and HAase are secreted in urine. In G2 and G3 bladder tumors, HA is degraded by HAase, resulting in the generation of angiogenic HA fragments, which, in turn, are secreted in urine. An elevated urinary HA level (> or = 500 ng/mg), indicating a positive HA test, suggests the presence of bladder cancer regardless of tumor grade. The urinary HAase levels correlate with the malignant potential of bladder cancer and are elevated (> or = 10 mU/mg) in the urine of patients with G2 and G3 bladder cancer. Combining the results from the HA and the HAase tests (the HA-HAase test) yields inferences, including the detection of bladder cancer and the evaluation of its grade. The overall 92% sensitivity of the HA-HAase test to detect bladder cancer is higher than the sensitivity of individual tests with little compromise in specificity. The HA-HAase test is equally sensitive for monitoring tumor recurrence. When compared with existing noninvasive tests, the HA-HAase test may be significantly less expensive and more accurate.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10696245     DOI: 10.1016/s0094-0143(05)70234-2

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  10 in total

Review 1.  Early bladder cancer: concept, diagnosis, and management.

Authors:  Hiroshi Kitamura; Taiji Tsukamoto
Journal:  Int J Clin Oncol       Date:  2006-02       Impact factor: 3.402

2.  Urinary hyaluronidase activity in rats infected with Blastocystis hominis--evidence for invasion?

Authors:  S Chandramathi; Kumar Govind Suresh; A A Mahmood; U R Kuppusamy
Journal:  Parasitol Res       Date:  2010-04-01       Impact factor: 2.289

3.  Urine cytology and adjunct markers for detection and surveillance of bladder cancer.

Authors:  Peggy S Sullivan; Jessica B Chan; Mary R Levin; Jianyu Rao
Journal:  Am J Transl Res       Date:  2010-07-25       Impact factor: 4.060

4.  Bladder cancer 2000: molecular markers for the diagnosis of transitional cell carcinoma.

Authors:  D Chao; S J Freedland; A J Pantuck; A Zisman; A S Belldegrun
Journal:  Rev Urol       Date:  2001

5.  Critical evaluation of urinary markers for bladder cancer detection and monitoring.

Authors:  Shahrokh F Shariat; Jose A Karam; Yair Lotan; Pierre I Karakiewizc
Journal:  Rev Urol       Date:  2008

6.  A Novel Splice Variant of HYAL-4 Drives Malignant Transformation and Predicts Outcome in Patients with Bladder Cancer.

Authors:  Vinata B Lokeshwar; Daley S Morera; Sarrah L Hasanali; Travis J Yates; Marie C Hupe; Judith Knapp; Soum D Lokeshwar; Jiaojiao Wang; Martin J P Hennig; Rohitha Baskar; Diogo O Escudero; Ronny R Racine; Neetika Dhir; Andre R Jordan; Kelly Hoye; Ijeoma Azih; Murugesan Manoharan; Zachary Klaassen; Sravan Kavuri; Luis E Lopez; Santu Ghosh; Bal L Lokeshwar
Journal:  Clin Cancer Res       Date:  2020-02-24       Impact factor: 12.531

Review 7.  Bladder tumor markers: from hematuria to molecular diagnostics--where do we stand?

Authors:  Samir P Shirodkar; Vinata B Lokeshwar
Journal:  Expert Rev Anticancer Ther       Date:  2008-07       Impact factor: 4.512

Review 8.  Alternatives to cytology in the management of non-muscle invasive bladder cancer.

Authors:  Gilad E Amiel; Tung Shu; Seth P Lerner
Journal:  Curr Treat Options Oncol       Date:  2004-10

9.  FRET based ratio-metric sensing of hyaluronidase in synthetic urine as a biomarker for bladder and prostate cancer.

Authors:  Rahul Chib; Sangram Raut; Rafal Fudala; Aaron Chang; Mark Mummert; Ryan Rich; Zygmunt Gryczynski; Ignacy Gryczynski
Journal:  Curr Pharm Biotechnol       Date:  2013       Impact factor: 2.837

10.  Urine-based assays for the detection of bladder cancer.

Authors:  Patrick Villicana; Bryant Whiting; Steve Goodison; Charles J Rosser
Journal:  Biomark Med       Date:  2009-06-01       Impact factor: 2.851

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.